1. Home
  2. BRKR vs STVN Comparison

BRKR vs STVN Comparison

Compare BRKR & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bruker Corporation

BRKR

Bruker Corporation

HOLD

Current Price

$39.08

Market Cap

5.5B

Sector

Industrials

ML Signal

HOLD

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

HOLD

Current Price

$16.53

Market Cap

4.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRKR
STVN
Founded
1960
1949
Country
United States
Italy
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Containers/Packaging
Sector
Industrials
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.2B
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
BRKR
STVN
Price
$39.08
$16.53
Analyst Decision
Buy
Hold
Analyst Count
13
2
Target Price
$49.54
$23.75
AVG Volume (30 Days)
2.3M
724.9K
Earning Date
05-04-2026
01-01-0001
Dividend Yield
0.51%
0.42%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,895,600,000.00
N/A
Revenue This Year
$5.75
$8.42
Revenue Next Year
$3.99
$9.27
P/E Ratio
N/A
$27.15
Revenue Growth
N/A
N/A
52 Week Low
$28.53
$13.91
52 Week High
$56.22
$28.00

Technical Indicators

Market Signals
Indicator
BRKR
STVN
Relative Strength Index (RSI) 39.73 51.77
Support Level $35.70 $13.91
Resistance Level $42.89 $16.69
Average True Range (ATR) 1.79 0.73
MACD 0.29 0.18
Stochastic Oscillator 58.84 85.84

Price Performance

Historical Comparison
BRKR
STVN

About BRKR Bruker Corporation

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Share on Social Networks: